This CPB is revised to state that degarelix is considered medically necessary for the treatment of men with advanced prostate cancer who cannot take other hormone therapies and who have refused surgical castration. This policy revision is supported by the FDA-approved indications for degarelix. This CPB has been revised to state that leuprolide is considered experimental and investigational for osteosarcoma and for autoimmune progesterone dermatitis of pregnancy.